ETFs Genmab A/S

GMAB

DK0010272202

Biotechnology & Medical Research

Market Closed - Nasdaq Copenhagen Other stock markets 16:20:00 04/12/2025 GMT			5-day change	1st Jan Change
2,062.00 ^DKK	+1.93%		+0.49%	+38.16%

12-04	Genmab A/S Presents at Citi Annual Global Healthcare Conference 2025, Dec-04-2025 09:45 AM
12-04	Genmab Closes $2.5 Billion Senior Notes Offering	MT

ETFs positioned on Genmab A/S

Name	Weight	AuM	Varia. Jan 1.	Investor
XACT NORDEN (UCITS ETF) - EUR	3.64%	1,412 M€	+0.37%	-
NOMURA NEXT FUNDS INTERNATIONAL EQUITY MSCI-KOKUSAI (YEN-HEDGED) ETF - JPY	0.75%	26 M€	+11.55%	-
VANECK WORLD EQUAL WEIGHT SCREENED UCITS ETF - EUR	0.56%	1,101 M€	+9.15%	-
VANECK MULTI-ASSET GROWTH ALLOCATION UCITS ETF - EUR	0.45%	31 M€	+3.40%	-
UBS (IRL) ETF PLC MSCI EUROPE ESG UNIVERSAL LOW CARBON SELECT UCITS ETF - ACC - EUR	0.31%	0 M€	-.--%	-
VANECK MULTI-ASSET CONSERVATIVE ALLOCATION UCITS ETF - EUR	0.19%	20 M€	+1.71%	-
AMUNDI INDEX MSCI WORLD SRI PAB - UCITS ETF DR (C) - EUR	0.14%	0 M€	-.--%	-
AMUNDI INDEX MSCI WORLD SRI PAB - UCITS ETF DR - HEDGED EUR (C)	0.14%	0 M€	-.--%	-
VANGUARD INTERNATIONAL EQUITY INDEX FUNDS - VANGUARD FTSE ALL-WORLD EX-US ETF	0.11%	33,076 M€	+19.85%	-
LEVERAGE SHARES PLC - 3X LONG TOTAL WORLD ETP	0.06%	1 M€	-.--%	-
NOMURA NEXT FUNDS INTERNATIONAL EQUITY MSCI-KOKUSAI (UNHEDGED) ETF - JPY	0.04%	386 M€	+15.39%	-
LYXOR MSCI WORLD CLIMATE CHANGE (DR) UCITS ETF - ACC - USD	0.04%	0 M€	-.--%	-
AMUNDI INDEX MSCI WORLD - UCITS ETF DR (C) - EUR	0.04%	0 M€	-.--%	-
AMUNDI INDEX MSCI WORLD UCITS ETF DR (D) - EUR	0.04%	0 M€	-.--%	-
AMUNDI MSCI WORLD CLIMATE TRANSITION CTB - UCITS ETF DR (C) - USD	0.04%	0 M€	-.--%	-
VANGUARD LIFESTRATEGY 80% EQUITY UCITS ETF ACC - EUR	0.04%	839 M€	+6.74%	-
AMUNDI MSCI WORLD CLIMATE PARIS ALIGNED PAB UCITS ETF DR (C) - USD	0.04%	0 M€	-.--%	-
VANGUARD LIFESTRATEGY 80% EQUITY UCITS ETF - DISTRIBUTING - EUR	0.03%	62 M€	+6.22%	-
RAREVIEW SYSTEMATIC EQUITY ETF - USD	0.03%	51 M€	+19.15%	-

1 2

Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows: - royalties (80.6%); - income from research and development (9.3%); - other (10.1%): primarily income from partnership agreement. At the end of 2024, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase. Net sales are distributed geographically as follows: Denmark (91.9%), the United States (4.2%) and Japan (3.9%).

Employees

2,681

Sector

Biotechnology & Medical Research

Calendar

12-05 - American Society of Hematology Meeting - Abstract Number:7251

More about the company